Therapeutic effects of colchicine in the management of peyronie's disease: a randomized double-blind, placebo-controlled study

ABSTRACT To determine effectiveness and safety of colchicine in Peyronie's disease. In all, 84 patients with Peyronie's disease who did not have calcified plaque were entered into

study. The mean disease duration was 15 months. A medical history was obtained, and physical examination, penile X-ray, and dynamic penile duplex ultrasound were performed. Patients were

randomly divided into group 1, those who received 0.5–2.5 mg colchicine daily for 4 months and group 2, who received placebo for the same period. Response to therapy was assessed

objectively, during dynamic penile duplex ultrasound, as well as subjectively using International Index of Erectile Function (IIEF) questionnaire and measurements of pain, duration of

disease, penile curvature, and plaque size. Differences before and after treatment and among the three Kelami classification groups were assessed. In total, 78 (92.8%) completed the whole

treatment schedule. Pain resolved in 60 and 63.6% of the patients treated with colchicine and placebo, respectively (_P_>0.05). After therapy, in subjects and controls a reduction in the

penile deformity was observed by 17.1 and 18.4% of the patients (_P_>0.05), and a decrease in plaque size was noticed by 10.5 and 10%, respectively (_P_>0.05). Objective measurements

did not demonstrate any difference in plaque size or penile curvature. There were no substantial differences in response to treatment based on duration of disease or within the three Kelami

classification groups. Significant drug-related adverse effects occurred in colchicine group and in two cases was treatment discontinued. Colchicine is no better than placebo in improvement

of pain, curvature angle, or plaque size in patients with Peyronie's disease. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS DAILY LOW-DOSE TADALAFIL MAY REDUCE THE PENILE CURVATURE

PROGRESSION RATE IN PATIENTS WITH ACUTE PEYRONIE’S DISEASE: A RETROSPECTIVE COMPARATIVE ANALYSIS Article 13 December 2022 COMBINATION THERAPY WITH TOPICAL ALPROSTADIL AND PHOSPHODIESTERASE-5

INHIBITORS AFTER FAILURE OF ORAL THERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION: A PROSPECTIVE, TWO-ARM, OPEN-LABEL, NON-RANDOMIZED STUDY Article 22 January 2021 PREVALENCE OF

POST-PROSTATECTOMY ERECTILE DYSFUNCTION AND A REVIEW OF THE RECOMMENDED THERAPEUTIC MODALITIES Article 17 November 2020 REFERENCES * Levine LA . Treatment of Peyronie's disease with

intralesional verapamil injection. _J Urol_ 1997; 158: 1395–1401. Article  CAS  Google Scholar  * Carson CC . Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it

effective? _Tech Urol_ 1997; 3: 135–140. CAS  PubMed  Google Scholar  * Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease. _J Urol_ 1990; 144: 1376–1381. Article

  CAS  Google Scholar  * Ralph DJ, Brooks MD, Bottazzo GF, Pyror JP . The treatment of Peyronie's disease with tamoxifen. _Br J Urol_ 1992; 70: 648–653. Article  CAS  Google Scholar  *

Morgan RJ, Pryor JP . Procarbazine (Natulan) in the treatment of Peyronie's disease. _Br J Urol_ 1978; 50: 111–116. Article  CAS  Google Scholar  * Akkus E et al. Is colchicine

effective in Peyronie's disease? A pilot study. _Urology_ 1994; 44: 291–296. Article  CAS  Google Scholar  * Winter CC, Khanna R . Peyronie's disease: results with dermo-jet

injection of dexamethasone. _J Urol_ 1975; 114: 898–903. Article  CAS  Google Scholar  * Gelbard MK, James K, Riach P, Dorey F . Collagenase versus placebo in the treatment of

Peyronie's disease: a double-blind study. _J Urol_ 1993; 149: 56–60. Article  CAS  Google Scholar  * Morales A, Bruce AW . The treatment of Peyronie's disease with parathyroid

hormone. _J Urol_ 1975; 114: 901–906. Article  CAS  Google Scholar  * Bartsch G, Menander-Huber KB, Marberger H . Orgotein, a new drug for the treatment of Peyronie's disease. _Eur J

Rheumatol Inflamm_ 1981; 4: 250–255. CAS  PubMed  Google Scholar  * Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human

Peyronie's disease fibroblast by interferons-alpha, -beta and -gamma. _Scand J Urol Nephrol_ 1991; 25: 89–94. Article  CAS  Google Scholar  * Incrocci L, Hop W, Slob A . Current sexual

functioning in 106 patients with Peyronie's disease treated with radiotherapy 9 years earlier. _Urology_ 2000; 56: 1030–1033. Article  CAS  Google Scholar  * Hauck E et al.

Extracorporeal shock wave therapy in the treatment of Peyronie's disease. _Eur Urol_ 2000; 38: 663–670. Article  CAS  Google Scholar  * Frank IN, Scott WW . The ultrasonic treatment of

Peyronie's disease. _J Urol_ 1971; 106: 83–88. Article  CAS  Google Scholar  * El-Sakka AI et al. The effect of surgical trauma on rat tunica albuginea. _J Urol_ 1998; 159: 1700–1706.

Article  CAS  Google Scholar  * Diegelmann RF, Peterkofsky B . Inhibition of collagen secretion from bone and cultured fibroblast by microtubular disruptive drugs. _Proc Natl Acad Sci USA_

1972; 69: 892–898. Article  CAS  Google Scholar  * Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of Erectile dysfunction.

_Urology_ 1997; 49: 620–625. Article  Google Scholar  * Kelami A . Classification of congenital and acquired penile deviation. _Urol Int_ 1983; 38: 822–826. Google Scholar  * Steward S,

Malto M, Sandberg L, Colburn KK . Increase serum level of anti-elastin antibodies in patients with Peyronie's disease. _J Urol_ 1994; 152: 105–111. Article  Google Scholar  * Somers KD

et al. Isolation and characterization of collagen in Peyronie's disease. _J Urol_ 1989; 141: 629–634. Article  CAS  Google Scholar  * Border WA, Ruoslahti E . Transforming growth factor

beta in disease: the dark side of tissue repair. _J Clin Invest_ 1992; 90: 1–7. Article  CAS  Google Scholar  * Taylor AC . The mechanism of colchicine inhibition of mitosis. I. Kinetics of

inhibition and the binding of H3-colchicine. _J Cell Biol_ 1965; 25: 145–150. Article  CAS  Google Scholar  * Tilney LG, Hiramoto Y, Marsland D . Studies on the microtubules in heliozoa. _J

Cell Biol_ 1966; 29: 77–82. Article  CAS  Google Scholar  * Ehrilich HP, Bornstein P . Microtubules in transcellular movement of procollagen. _Nature (New Biol)_ 1972; 238: 257–261. Article

  Google Scholar  * El-Sakka AI et al. The effects of colchicine on a Peyronie's-like condition in an animal model. _J Urol_ 1999; 161: 1980–1983. Article  CAS  Google Scholar  *

Kadioglu A et al. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. _Int J Impot Res_ 2000; 12: 169–175. Article 

CAS  Google Scholar  * Claudio T et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. _J Urol_ 1999; 162: 2003–2008. Article  Google Scholar  * Levine LA, Goldman KE,

Greenfield JM . Experience with intraplaque injection of verapamil for Peyronie's disease. _J Urol_ 2002; 168: 621–626. Article  CAS  Google Scholar  * Husain J et al. Extracorporeal

shockwave therapy in the management of Peyronie's disease. _Br J Urol_ 2000; 68: 466–468. Article  Google Scholar  * Williams J, Thomas GG . The natural history of Peyronie's

disease. _J Urol_ 1970; 73: 75–79. Article  Google Scholar  * Kadioglu A . Lessons learned from 307 men with Peyronie's disease. _J Urol Suppl_ 2001; 165: 202, abstract 838. Google

Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urology, Medicine Faculty, Military University of Medical Sciences, Tehran, Iran M R Safarinejad

Authors * M R Safarinejad View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to M R Safarinejad. RIGHTS AND PERMISSIONS

Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Safarinejad, M. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind,

placebo-controlled study. _Int J Impot Res_ 16, 238–243 (2004). https://doi.org/10.1038/sj.ijir.3901185 Download citation * Received: 03 June 2003 * Revised: 02 October 2003 * Accepted: 07

October 2003 * Published: 19 February 2004 * Issue Date: 01 June 2004 * DOI: https://doi.org/10.1038/sj.ijir.3901185 SHARE THIS ARTICLE Anyone you share the following link with will be able

to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative KEYWORDS * Peyronie's disease * colchicine * drug treatment